Last reviewed · How we verify
i.v. recombinant human C1 inhibitor
At a glance
| Generic name | i.v. recombinant human C1 inhibitor |
|---|---|
| Also known as | rhC1INH |
| Sponsor | Pharming Technologies B.V. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients (PHASE2)
- Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks (PHASE3)
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema (PHASE2)
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- i.v. recombinant human C1 inhibitor CI brief — competitive landscape report
- i.v. recombinant human C1 inhibitor updates RSS · CI watch RSS
- Pharming Technologies B.V. portfolio CI